# A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

> **NCT06862791** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 377 (actual)

## Conditions studied

- Obesity or Overweight

## Interventions

- **DRUG:** AZD9550
- **DRUG:** AZD6234
- **DRUG:** Placebo comparator

## Key facts

- **NCT ID:** NCT06862791
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-18
- **Primary completion:** 2026-05-25
- **Final completion:** 2026-05-25
- **Target enrollment:** 377 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06862791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06862791, "A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06862791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*